Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON PEN versus FORTAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON PEN versus FORTAMET.
BYDUREON PEN vs FORTAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
2 mg subcutaneously once every 7 days (weekly)
Initial: 500 mg orally twice daily or 1000 mg orally once daily; titrate in increments of 500 mg weekly; maximum daily dose: 2000 mg.
None Documented
None Documented
Terminal elimination half-life is 2.4 hours following subcutaneous administration; due to extended-release microspheres, systemic exposure is sustained over 10 weeks with multiple dosing (effective half-life ~2 weeks).
Terminal elimination half-life is approximately 6.2 hours (range 4–9 hours) in patients with normal renal function; half-life is prolonged in renal impairment (up to 18 hours in moderate impairment and 24 hours in severe impairment).
Renal excretion of intact exenatide via glomerular filtration and proteolytic degradation; approximately 100% of administered dose eliminated via renal pathways (urine) as intact peptide and metabolites.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; the remainder is excreted fecally (via bile).
Category C
Category C
Antidiabetic
Antidiabetic